COVID-19 Vaccines 2023

COVID-19 Vaccines March 2023

Innovative vaccine platforms such as DNA, mRNA, virus-like particles, viral vector, recombinant protein, and live attenuated and inactivated virus approaches have developed COVID-19 vaccines.

On August 23, 2021, the U.S. Food and Drug Administration (FDA) Authorized the Approved various versions of the Pfizer-BioNTech mRNA Comirnaty vaccine. It also has Approved the SpikeVax from Moderna, Inc., and the Jcovden vaccine was Authorized as of June 2022. In addition, on July 13, 2022, the FDA authorized Novavax's protein-based COVID-19 vaccine.

The FDA published an article on January 13, 2023: Identify Preliminary COVID-19 Vaccine Safety Signal for Persons 65 Years and Older. And on January 26, 2023, the FDA's Vaccines and Related Biological Products Advisory Committee is review this Briefing Document.

An Original Investigation conducted by researchers from the U.S. CDC VISION Network and published by The JAMA Network Open on March 15, 2023, found vaccine effectiveness of three doses of the monovalent mRNA COVID-19 against hospitalization was 68% for up to 4 months but then decreased to 36% during the Omicron BA.4 and BA.5 era.

And Intensive care unit admission or death occurred in 21.4% of hospitalized COVID-19 patients during the BA.1 period but only 14.7% during BA.4 and BA.5 (0.17).

Data reported in January 2023 indicates about 13 billion doses of COVID-19 vaccines have been administered globally, with 89% of health workers and 81% of older adults (over 60 years) having completed the primary two-dose series.

The European Medicines Agency (EMA) has Authorized COVID-19 vaccines as of January 2023. Furthermore, the U.K.'s Joint Committee on Vaccination and Immunisation confirmed that after February 12, 2023, the U.K. had reduced access to COVID-19 vaccine booster doses. In late February 2023, France announced reduced access to COVID-19 vaccines.

COVID-19 Vaccine Studies 2023

Additional vaccine news is published at PrecisionVaccinations.com/vaccines.

COVID-19 Antivirals 2023

The U.S. FDA and EMA have Approved and Authorized various antivirals (oral and IV) to treat COVID-19 infections.

SARS-CoV-2 9 Monoclonal Antibody 2023

The U.S. FDA and the EMA authorized monoclonal antibody therapies during the COVID-19 pandemic.